Clinical Scorecard: Linking Combined Allergic Rhinitis and Asthma Syndrome in Pediatric Patients to Nitric Oxide: Insights into Mechanisms, Clinical Implications, and Research Developments

At a Glance

Key Highlights

• CARAS is prevalent in children, with AR affecting 10%-30% and asthma 5%-15%.
• FeNO and nNO are significant biomarkers for CARAS diagnosis and monitoring.
• Th2-type immune inflammation is a key pathological feature of CARAS.
• Traditional diagnostic methods are subjective and challenging in young children.
• Nitric oxide plays a crucial role in airway inflammation and disease progression.

Guideline-Based Recommendations

Diagnosis

• Utilize symptom-based scoring systems like ARIA and GINA.
• Incorporate pulmonary function testing where feasible.

Management

• Antihistamines and inhaled corticosteroids (ICS) are primary treatments.
• Monitor exhaled nitric oxide levels to guide medication adjustments.

Monitoring & Follow-up

• Regular assessment of FeNO and nNO levels to evaluate treatment response.

Risks

• Prolonged ICS use may lead to adverse effects such as growth retardation.

Patient & Prescribing Data

Children diagnosed with CARAS

Conventional drugs relieve symptoms but do not cure the condition.

Clinical Best Practices

• Focus on child-specific analysis of NO-related pathogenic mechanisms.
• Integrate FeNO and nNO measurements for comprehensive assessment.

Related Resources & Content

• World Allergy Organization
• PubMed Database